Table 7.

Analysis of factors potentially influencing overall global improvement (physician’s assessment) (efficacy analysis population)

Item	N	Overall global improvement		Univariate			Multivariate
		Improved patients	Improvement rate (%)	Odds ratio	95% CI	p value	Odds ratio	95% CI	p value
Overall	2439	1806	74.0
Sex
Male	943	686	72.7	1			1
Female	1496	1120	74.9	1.116	0.928–1.343	0.245	1.126	0.876–1.447	0.355
Age (years)
< 65	997	731	73.3	1			1
≥ 65 to < 85	1213	898	74.0	1.037	0.858–1.255	0.705	1.163	0.876–1.543	0.296
≥ 85	229	177	77.3	1.239	0.882–1.739	0.217	1.172	0.720–1.906	0.524
BMI (kg/m2)
< 25.0	1046	782	74.8	1			1
≥ 25.0	377	276	73.2	0.923	0.706–1.205	0.554	0.973	0.736–1.285	0.846
Duration of insomnia (years)
< 1	968	756	78.1	1			1
≥ 1 to < 10	1124	814	72.4	0.736	0.602–0.900	0.003	0.741	0.553–0.994	0.045
≥ 10	347	236	68.0	0.596	0.454–0.783	< 0.001	0.600	0.404–0.890	0.011
Schizophrenia
No	2321	1728	74.5	1			1
Yes	76	52	68.4	0.743	0.454–1.217	0.238	0.781	0.417–1.464	0.441
Depression
No	2012	1500	74.6	1			1
Yes	386	280	72.5	0.902	0.706–1.152	0.407	1.051	0.730–1.512	0.790
Manic-depressive illness
No	2333	1742	74.7	1			1
Yes	64	38	59.4	0.495	0.298–0.823	0.007	0.736	0.364–1.490	0.395
Anxiety disorder
No	2243	1669	74.4	1			1
Yes	154	111	72.1	0.888	0.617–1.278	0.522	1.405	0.848–2.329	0.187
Dementia
No	2279	1692	74.2	1			1
Yes	118	88	74.6	1.018	0.665–1.556	0.936	1.077	0.610–1.904	0.797
Concomitant medication
No	727	572	78.7	1			1
Yes	1695	1223	72.2	0.702	0.571–0.864	< 0.001	0.716	0.520–0.987	0.041
Initiation status
Naïve	1446	1136	78.6	1			1
Switch	538	344	63.9	0.484	0.390–0.601	< 0.001	0.675	0.496–0.920	0.013
Add-on	410	292	71.2	0.675	0.527–0.865	0.002	0.863	0.603–1.238	0.424

BMI body mass index, CI confidence interval